---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Pharmacodynamics"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Pharmacodynamics. Topics: Aqueous humor C1q target engagement: phase Ib glaucoma study, Serum C1q after intravitreal dosing: phase Ia glaucoma study, Company summary of phase 1 target engagement, Dose selection for monthly intravitreal injection, and 5 further topics. 9 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### Aqueous humor C1q target engagement: phase Ib glaucoma study

> “Correspondingly, mean (SD) and median (min, max) unbound C1q at day 1 (preinjection) was 100.1 (99.9) and 51.6 (16, 254) ng/ml in sham, 110.0 (109.5) and 65.7 (23, 293) in the ANX007 2.5 mg dose group, and 110.0 (83.1) and 86.8 (14, 222) in the ANX007 5.0 mg dose groups.”
> “Unbound C1q was reduced to undetectable levels at day 29 (< 0.6 ng/ml) in aqueous humor at both dose levels in all subjects”
> “Full engagement of C1q in the aqueous humor at day 29 in all treated subjects supports monthly or less-frequent dosing of ANX007 in future clinical studies.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-2.1.2.6.2-2"></a>

### Serum C1q after intravitreal dosing: phase Ia glaucoma study

> “serum unbound C1q levels were unchanged over the period of the study”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-2.1.2.6.2-3"></a>

### Company summary of phase 1 target engagement

> “The studies showed that vonaprument was well-tolerated at all doses (1 mg, 2.5 mg and 5 mg) and achieved complete suppression of C1q at 2.5 mg and 5 mg.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-2.1.2.6.2-4"></a>

### Dose selection for monthly intravitreal injection

> “Significant Reduction in Free C1q through 4 Weeks after Single Vonaprument Dose”
> “Patient aqueous humor PK/PD supports 5mg at least monthly intravitreal injection”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-2.1.2.6.2-5"></a>

### In vitro binding and complement pathway selectivity

> “The binding affinity of ANX007 to purified human C1q and to C1q captured from human and cynomolgus monkey serum were similar, with EC50 values of 136 pM (7.7 ng/mL), 147 pM (8 ng/mL), and 179 pM (9.5 ng/mL), respectively”
> “ANX007 specifically inhibited classical complement-mediated activation at 6 nM (300 ng/mL) and had no effect on the lectin or the alternative pathway”

Source: [Grover et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9907371/)

<a id="topic-2.1.2.6.2-6"></a>

### Ocular target engagement in nonhuman primates

> “In contrast, suppression of free-C1q levels was maintained at days 44 and 59 in all tissues except the optic nerve.”
> “C1q inhibition was near complete in all samples at day 44, approximately 2 weeks after the second dose.”
> “These results demonstrate that aqueous humor C1q target engagement is reflected in C1q lowering in both vitreous and the retina.”
> “Importantly, in clinical studies where vitreous and ocular tissues cannot be sampled, these data support the relevance of aqueous humor target engagement as a surrogate for retinal target engagement.”

Source: [Grover et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9907371/)

<a id="topic-2.1.2.6.2-7"></a>

### Preclinical pharmacology: photo-oxidative photoreceptor damage model

> “In support of this hypothesis, we found that either deletion or pharmacologic inhibition of C1q was protective in an animal model of photoreceptor neuron loss induced by photo-oxidation, as shown below.”
> “C1q inhibition was shown to be protective of photoreceptor cells and retinal function in a model of photoreceptor cell damage induced by light.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-2.1.2.6.2-8"></a>

### Preclinical pharmacology: intravitreal and systemic anti-C1q in a light damage model

> “Genetic deletion or pharmacological inhibition of C1q provided protection against photoreceptor cell loss and preserved receptor cell function, even when inhibition was provided after damage had occurred”
> “Interestingly, while local (intravitreal) administration of an anti-C1q antibody was protective, systemic administration was not—presumably due to local production of C1q in the retina and to lower levels of antibody penetration into the eye with systemic dosing.”

Source: [Yednock et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9641935/)

<a id="topic-2.1.2.6.2-9"></a>

### Preclinical pharmacology: microglia, synapses, and photoreceptors after light-induced damage

> “Upon Photoreceptor Damage in a Rodent Model, Microglia Engulf C1q-Coated Synapses”
> “C1q inhibition reduced reactive microglia, synapse loss, & photoreceptor loss, and protected function”

Source: [Stanga (2025)](https://annexonbio.com/wp-content/uploads/2025/09/Stanga-EURetina-2025-C1q-inhibition-HD-GA_.pdf)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
